Literature DB >> 10485485

p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma.

C M Vollmer1, A Ribas, L H Butterfield, V B Dissette, K J Andrews, F C Eilber, L D Montejo, A Y Chen, B Hu, J A Glaspy, W H McBride, J S Economou.   

Abstract

An E1B gene-attenuated adenovirus (dl1520) has been proposed to have a selective cytolytic activity in cancer cells with a mutation or deletion in the p53 tumor suppressor gene (p53-null), a defect present in almost half of human hepatocellular carcinomas (HCCs). In this study, the in vitro and in vivo antitumor activity of dl1520 was investigated focusing on two human HCC cell lines, a p53-wild type (p53-wt) cell line and a p53-null cell line. dl1520 was tested for in vitro cytopathic effects and viral replication in the human HCC cell lines Hep3B (p53-null) and HepG2 (p53-wt). The in vivo antitumor effects of dl1520 were investigated in tumors grown s.c. in a severe combined immunodeficient mouse model. In addition, the combination of dl1520 infection with systemic chemotherapy was assessed in these tumor xenografts. At low multiplicities of infection, dl1520 had an apparent p53-dependent in vitro viral growth in HCC cell lines. At higher multiplicities of infection, dl1520 viral replication was independent of the p53 status of the target cells. In vivo, dl1520 significantly retarded the growth of the p53-null Hep3B xenografts, an effect augmented by the addition of cisplatin. However, complete tumor regressions were rare, and most tumors eventually grew progressively. dl1520 had no effect on the in vivo growth of the p53-wt HepG2 cells, with or without cisplatin treatment. The E1B-deleted adenoviral vector dl1520 has an apparent p53-dependent effect in HCC cell lines. However, this effect is lost at higher viral doses and only induces partial tumor regressions without tumor cures in a human HCC xenograft model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485485

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

Authors:  B R Dix; S J Edwards; A W Braithwaite
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.

Authors:  K Doronin; M Kuppuswamy; K Toth; A E Tollefson; P Krajcsi; V Krougliak; W S Wold
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Recombinant baculovirus as a highly potent vector for gene therapy of human colorectal carcinoma: molecular cloning, expression, and in vitro characterization.

Authors:  Arghya Paul; Barbara A Jardin; Arun Kulamarva; Meenakshi Malhotra; Cynthia B Elias; Satya Prakash
Journal:  Mol Biotechnol       Date:  2010-06       Impact factor: 2.695

4.  Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells.

Authors:  D Yang; L Li; H Liu; L Wu; Z Luo; H Li; S Zheng; H Gao; Y Chu; Y Sun; J Liu; L Jia
Journal:  Cell Death Differ       Date:  2012-08-31       Impact factor: 15.828

5.  MicroRNA-30a sensitizes tumor cells to cis-platinum via suppressing beclin 1-mediated autophagy.

Authors:  Zhenyou Zou; Linping Wu; Hanying Ding; Yang Wang; Yaqin Zhang; Xuejiao Chen; Xi Chen; Chen-Yu Zhang; Qipeng Zhang; Ke Zen
Journal:  J Biol Chem       Date:  2011-12-08       Impact factor: 5.157

Review 6.  Gene therapy of liver cancer.

Authors:  Ruben Hernandez-Alcoceba; Bruno Sangro; Jesus Prieto
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

7.  Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical Trials.

Authors:  A D Hartkopf; T Fehm; M Wallwiener; U Lauer
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-02       Impact factor: 2.915

8.  Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein.

Authors:  Maike Sieben; Kerstin Herzer; Maja Zeidler; Vera Heinrichs; Barbara Leuchs; Martin Schuler; Jan-J Cornelis; Peter-R Galle; Jean Rommelaere; Markus Moehler
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

9.  Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5.

Authors:  J-L Hsieh; C-L Wu; M-D Lai; C-H Lee; C-S Tsai; A-L Shiau
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

10.  2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells.

Authors:  David Sharon; Michael Schümann; Sheena MacLeod; Robyn McPherson; Shyambabu Chaurasiya; Andrew Shaw; Mary M Hitt
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.